Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Children's National and George Washington University receive NIH Clinical and Translational Science Award

Children's National Medical Center, in partnership with The George Washington University Medical Center, has received a prestigious Clinical and Translational Science Award (CTSA) from the National Center for Research Resources of the National Institutes of Health.

15 Jul 2010

First triple-organ transplantation performed on young Brenham resident at Texas Children's Hospital

Texas Children's Hospital in Houston has performed the hospital's first triple-organ transplant on a 16-year-old Brenham resident. The patient, Taylor Sherrouse, underwent a 13-hour surgery on Tuesday, June 22 to replace her heart, lungs and liver, which had been severely damaged by cystic fibrosis. Taylor is one of only three pediatric patients in the country this decade to receive heart, lungs and liver in one operation.

15 Jul 2010

ABL signs international distribution agreement for Virco BVBA's HIV resistance interpretation system

Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA's HIV resistance interpretation system.

13 Jul 2010

Research findings could offer new approach to diabetes therapy, nutrition experts say

Nutrition experts at Oregon State University have essentially "cured" laboratory mice of mild, diet-induced diabetes by stimulating the production of a particular enzyme. The findings could offer a new approach to diabetes therapy, experts say, especially if a drug could be identified that would do the same thing, which in this case was accomplished with genetic manipulation.

13 Jul 2010

CF patients recover from exacerbations equally well when treated at home or in hospital: Researchers

Patients with cystic fibrosis recover from exacerbations equally well if they are treated at home or in a hospital, according to researchers from Johns Hopkins University. Furthermore, longer treatment with antibiotics does not appear to offer any additional benefit over shorter courses.

8 Jul 2010

Researchers develop computer program to accurately simulate protein folding

All proteins self-assemble in a fraction of the blink of an eye, but it can take a long time to mimic the process. And there has been no guarantee of success, even with the most powerful computers - until now.

8 Jul 2010

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.

7 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Three Rivers Pharmaceuticals, LLC, today received expanded labeling from the U.S. Food and Drug Administration (FDA) to include daily use of INFERGEN (Consensus Interferon) in combination with ribavirin (RBV) for retreatment of chronic hepatitis C patients. The expanded labeling targets hepatitis C patients who need retreatment.

6 Jul 2010

Eli Lilly, Alnara sign definitive merger agreement

Eli Lilly and Company and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT).

2 Jul 2010

DARA BioSciences suspends $10M underwritten public offering

On May 17, 2010, DARA BioSciences, Inc. issued a press release announcing that it had commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. DARA has decided to indefinitely suspend the offering, effective immediately. Several important factors have influenced this decision.

2 Jul 2010

Researchers identify a set of molecular signatures for biliary atresia

Researchers have identified a set of "molecular signatures" for biliary atresia - the most common diagnosis leading to liver transplant in children - that can help identify the progression of disease at diagnosis and predict clinical outcomes.

1 Jul 2010

Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Aeolus Pharmaceuticals, Inc. reported that researchers from National Jewish Health and the University of Colorado Anschutz Medical Campus have completed studies demonstrating that AEOL 10150 provides statistically significant protection of the skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in mice and in a human cell culture model.

30 Jun 2010

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it's often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

29 Jun 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

SurgiVision's ClearPoint system granted 510(k) clearance for neurological interventional procedures

DARA BioSciences, Inc., announced today that SurgiVision, Inc., a privately held company of which DARA owns 1,613,258 shares and warrants to purchase an additional 405,000 shares, has received 510(k) clearance from the Food and Drug Administration (FDA) to market their ClearPoint system in the United States for general neurological interventional procedures.

29 Jun 2010

CMMC installs Toshiba's Vantage Titan MR system to accommodate bariatric patients

Obesity is a growing trend in the United States, requiring hospitals to provide medical imaging technology designed to accommodate bariatric patients without compromising diagnostic confidence or patient comfort. To accomplish this goal, Central Mississippi Medical Center in Jackson, Miss., a bariatric center of excellence, recently installed Toshiba America Medical Systems, Inc.'s Vantage Titan MR system.

28 Jun 2010

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

We've all experienced the strong heartbeat that accompanies emotions such as fear and rage. But can the body's natural response to these emotions be used to combat heart failure? Results of a study published online today in the journal Circulation Research present a strong case.

25 Jun 2010

Update on Regulus and sanofi-aventis collaboration

Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. announced today that, as a result of the newly formed alliance Regulus has established with sanofi-aventis, each company will receive a payment of $1.8 million from Regulus. This represents 7.5% of the $25 million upfront payment from sanofi-aventis to Regulus.

23 Jun 2010

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Scientists at Cincinnati Children's Hospital Medical Center have discovered that a diet with high levels of fructose - levels equivalent to that in high fructose corn syrup - and of trans fats not only increases obesity, but also leads to significant fatty liver disease with scar tissue.

23 Jun 2010

Fibrosis News and Research

Further Reading

Children's National and George Washington University receive NIH Clinical and Translational Science Award

First triple-organ transplantation performed on young Brenham resident at Texas Children's Hospital

ABL signs international distribution agreement for Virco BVBA's HIV resistance interpretation system

Research findings could offer new approach to diabetes therapy, nutrition experts say

CF patients recover from exacerbations equally well when treated at home or in hospital: Researchers

Researchers develop computer program to accurately simulate protein folding

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Three Rivers Pharmaceuticals receives FDA expanded labeling for INFERGEN

Eli Lilly, Alnara sign definitive merger agreement

DARA BioSciences suspends $10M underwritten public offering

Researchers identify a set of molecular signatures for biliary atresia

Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

SurgiVision's ClearPoint system granted 510(k) clearance for neurological interventional procedures

CMMC installs Toshiba's Vantage Titan MR system to accommodate bariatric patients

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

Update on Regulus and sanofi-aventis collaboration

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News